| |
|
|
| Year : 2009 | Volume
: 20
| Issue : 5 | Page : 741-752 |
|
| The protective effect of thymoquinone, an anti-oxidant and anti-inflammatory agent, against renal injury: A review |
|
|
Ahmed Ragheb1, Ahmed Attia1, Walid Shehab Eldin1, Fawzy Elbarbry2, Sana Gazarin3, Ahmed Shoker1
1 Department of Medicine, Division of Nephrology, Royal University Hospital, University of Saskatchewan, Saskatoon, SK, Canada
2 School of Pharmacy, Pacific University, Hillsboro, OR, USA
3 Department of General Medicine, College of Medicine, Menofyia University, Menofyia, Egypt
Click here for correspondence address and email
| Date of Web Publication | 2-Sep-2009 |
|
|
 |
|
 Abstract | | |
Thymoquinone (TQ), 2-Isopropyl-5-methyl-1, 4-benzoquinone, is one of the most active ingredients of Nigella Sativa seeds. TQ has a variety of beneficial properties including antioxidative and anti-inflammatory activities. Studies have provided original observations on the role of oxidative stress and inflammation in the development of renal diseases such as glomerulonephritis and drug-induced nephrotoxicity. The renoprotective effects of TQ have been demonstrated in animal models. Also, TQ has been used successfully in treating allergic diseases in humans. The aim of this review is to highlight the importance of reactive oxygen species in renal pathophysiology and the intriguing possibility for a role of TQ in the prevention of and/or protection from renal injury in humans.
How to cite this article:
Ragheb A, Attia A, Eldin WS, Elbarbry F, Gazarin S, Shoker A. The protective effect of thymoquinone, an anti-oxidant and anti-inflammatory agent, against renal injury: A review. Saudi J Kidney Dis Transpl 2009;20:741-52 |
How to cite this URL:
Ragheb A, Attia A, Eldin WS, Elbarbry F, Gazarin S, Shoker A. The protective effect of thymoquinone, an anti-oxidant and anti-inflammatory agent, against renal injury: A review. Saudi J Kidney Dis Transpl [serial online] 2009 [cited 2020 Dec 2];20:741-52. Available from: https://www.sjkdt.org/text.asp?2009/20/5/741/55356 |
| Introduction | |  |
Among the promising medicinal plants, Nigella Sativa (NS), is an amazing herb with a rich historical and religious background. The seeds of NS are the source of the active ingredients of this plant. Historically, the black seed has been referred to in the Islamic tradition as having healing powers. [1] It has been used in folk medicine in the Middle and Far East for many years as a traditional medicine for a wide range of illnesses including bronchial asthma, headache, dysentery, infections, obesity, back pain, hypertension and gastrointestinal problems. [2] Black seed extract, however, has been used in few clinical trials. In one of those trials, NS oil extract, administered in a dose of 40 mg/kg, significantly improved the clinical symptoms in patients with allergic diseases such as bronchial asthma, allergic rhinitis and atopic eczema [3] Adverse effects did not occur, except in children receiving high doses of 80 mg/kg. It was recommended that, when used in children, it should be administered in weight-adapted doses given after meals. Its tolerability was further confirmed in another study. [4]
N. sativa seeds contain 36-38% fixed oils, proteins, alkaloids, saponin and 0.4-2.5% essential oil. [5] By High Performance Liquid Chromatography (HPLC) analysis of NS essential oil, thymoquinone (TQ), dithymoquinone (DTQ), thymohydroquinone (THQ), and thymol (THY) are considered the main active ingredients [6] [Figure 1].
The most prominent activity of TQ is its antioxidant effect and therefore, an overview of the effect of reactive oxygen species (ROS) on the kidney is presented first, followed by presentation of other properties of TQ.
| Reactive Oxygen Species and the Kidney | | |
ROS, including super-oxide anion radical (O2 - ), hydrogen peroxide (H2O2), peroxynitrite (ONOO), hydroxyl radical (OH - ) and hypochlorous acid (HOCl - ) are by-products of the normal metabolic processes in the cells. The deleterious effects of oxygen are believed to result from its metabolic reduction to these highly reactive and toxic species. [7] Homology searches in human genome database resulted in the discovery of six novel NADPH oxidase enzymes. They all have, at least partially, similar structure and generate ROS in response to various stimuli. High-level ROS generation at specific sites by non-phagocytic oxidases suggests that they have additional unique functions. [8] Among them, the Nox4 is believed to be most abundant in the kidney and plays several roles in renal physiology and pathology. Nox4, the renal oxidase, was first described as a renal-specific oxidase and was thus originally named Renox. It was shown that Nox4 is involved in angiotensin II-induced ROS production in kidney mesangial cells. [9]
ROS and Renal Physiology
ROS, nitric oxide (NO) and their interaction are important regulators of renal function. Several studies have indicated that production of both O 2 - and NO are involved in the normal kidney and vascular functions. Both may act as intermediate signaling processes involved in maintaining vascular tone and tubular function. Specific roles in normal renal function for ROS, however, have now been identified. O 2 generates much of its biological effects by scavenging NO produced by the kidney. [10]
ROS and Renal Pathology
Clinical and experimental evidences of renal damage mediated by oxidative stress can be grouped under: a) glomerular, b) tubulointers- titial, and c) endothelial alterations [Figure 2].
a) Glomerular alterations
Oxidative injury may alter the structure and function of the glomerulus, mainly because of the effect of ROS on the mesangial and endothelial cells. [11] Oxidative stress participates in renal damage induced by hyperlipoproteinemia. [12] Oxidation of LDL molecules by mesangial cells could occur, [13] thereby activating apoptosis pathway of the endothelial and mesangial cells, as shown by in vitro studies on these human cells, an effect prevented by antioxidants. [14] Lipoprotein glomerulopathy has been characterized by the development of glomerulosclerosis and a relatively rapid progression to renal impairment. [15]
Oxidative stress could also be involved in other inflammatory glomerular lesions caused by a eries of mediators including cytokines and chemokines that lead to leukocyte activation, production of ROS, and increased glomerular damage. Various stimuli like nuclear factor- &$954;B (NF-κB) have been identified as promoters of inflammatory responses occurring in mesangial cells. [16]
b) Tubulointerstitial alterations
Macromolecules appear in the urinary space because of loss of glomerular permselectivity occurring in chronic renal disease. Thus, renal tubular epithelium can be exposed to injurious chemical species. Among these molecules are the oxidized LDL molecules (LDL-ox), [17] transition metals, [18] hemoglobin and myoglobin, [19] or potentially nephrotoxic drugs. The exposure of tubular cells to LDL-ox may result in tubulointerstitial damage due to the induction of a pro-oxidant environment. [20] In turn; this oxidative stimulus may induce the activation of heme-oxygenase enzyme, an enzyme that catalyzes the degradation of the heme groups of hemoglobin and myoglobin, [21] two heme pigments found in the urinary space of numerous glomerulopathies in which the glomerular barrier is impaired. Subsequently, iron liberation results in tubular production of OH - radicals and lipid peroxidation.
The accumulation of macrophages within the interstitial space of the renal cortex plays a pathogenic role in the development of tubular injury and interstitial fibrosis in progressive chronic renal diseases. [21] Proximal tubular epithelial cells are thought to mediate interstitial macrophage infiltration because of their anatomic position and ability to produce chemotactic cytokines, chemokines, and other inflammatory mediators. ROS induces gene expression of these mediators in the tubular epithelial cells, resulting in the recruitment of leukocytes. In renal tubular cells, the expression of chemokines, such as Monocyte Chemoattractant Protein (MCP)-1, MCP-3, Macrophage Inflammatory Protein-1 (MIP-1), and T cell activation gene 3, precedes the production of infiltrates containing monocytes, macrophages, and T lymphocytes in experimental acute tubulointerstitial nephritis. [22]
c) Endothelial dysfunction
Increased ROS production has been associated with proliferation of vascular smooth muscle cells and with the pathogenesis of renal hypertension. [23] Numerous effects of ROS in the regulation of vascular functions, mainly vasodilation, are mediated by NO. Increased vascular O 2 -production can lead to reduced amounts of bioavailable NO and impaired endotheliumdependent relaxation. [24]
Evidence for a role for ROS in various kidney diseases
Research laboratories have utilized in-vivo biomarkers to describe increased oxidative stress in uremic patients. [25] Although renal diseases are associated with oxidative stress and reduction of NO, it is difficult to determine if this relationship is a cause or a consequence of disease. [10] Experimental models of kidney diseases provide a good evidence to support the role of ROS in the pathogenesis of kidney disease [Table 1].
a) Glomerulonephritis (GN)
The role of oxidative stress has been confirmed in the pathogenesis of several models of GN, either leukocyte-dependent or independent.
1) Leukocyte-dependent GN
Leukocytes can cause proteinuria (a hallmark of glomerular diseases) by damaging the Glomerular Basement Membrane (GBM). The degradation of the GBM by stimulated neutrophils is caused by the activation of a latent metalloproteinase (MPO) enzyme by HOCl or a similar oxidant that is generated by the MPO-H2O2-halide system. [26] Anti-GBM and mesangial proliferative GN are two well-characterized models of GNs in which oxidative stress has been demonstrated to induce proteinuria. [27] In an anti-GBM antibody model, treatment with catalase markedly reduced proteinuria, [28] and the use of OH- scavenger or iron chelator significantly attenuated proteinuria. [29] In a mesangial proliferative GN model, treatment with antioxidant α-lipolic acid resulted in reduced generation of oxidants, and significant improvement in glomerular injury as measured histologically, and reduced expression of TGF-α1. [30]
2) Leukocyte-independent GN
The ability of glomerular cells to generate oxidants suggests that they may be important mediators of glomerular injury in glomerular diseases that lack infiltrating leukocytes. An animal model of minimal-change disease is induced by a single intravenous injection of puromycin aminonucleoside. Feeding rats a selenium-deficient diet resulted in marked diminution of GSH-Px and was accompanied by significant proteinuria, suggesting an important protective role of GSH-Px in this model of glomerular disease. Similarly, inhibition of SOD augments puromycin-induced proteinuria. [27]
3) Ischemia/reperfusion injury
New evidence suggests that ROS have a crucial role in the pathogenesis of ischemia/ reperfusion injury [31],[32] and acute rejection of renal allograft. [33],[34] The mechanisms involved in renal damage and dysfunction by ROS production during ischemia/reperfusion is still incompletely understood. Immunosuppressive drugs such as cyclosporine A (CsA) induce oxidative stress in the renal allograft, through vasoconstriction mediated by NO inhibition. [35] NADPH oxidase and xanthine oxidase activities were increased in experimental renal allograft, associated with increased ROS generation and signs of acute rejection. [34] Inhibition of xanthine oxidase with tungsten markedly suppressed ROS production, inflammation and signs of rejection, suggesting that it is the main source of ROS after transplantation. The ROS scavenger production correlates with also improved renal function and decreased renal tubular damage and mortality. [36] Several agents with anti-oxidant properties have been shown to be renoprotective in animal models of ischemia/ reperfusion, [37] not only by decreasing ROS but also through restoring the antioxidant enzymes.
4) Acute renal failure
Oxidative stress in patients with acute renal failure (ARF) is related to the imbalance between the production of ROS and the antioxidant system. Patients with severe ARF have lower plasma thiols (index of anti-oxidant capacity) and higher carbonyl levels (index of oxidative injury) than healthy subjects and patients with end-stage renal disease. [38]
5) Chronic renal failure
In the rat model of chronic renal failure (CRF) with five-sixths nephrectomy, renal expression of the anti-oxidant enzymes CAT and GSH-Px was reduced, suggesting that CRF suppresses the renal anti-oxidant defense system. [39] Treatment with the anti-oxidant N-acetylcysteine (NAC), however, improved the kidney function in this model. [40] NAC preserved GFR, lowered lipid peroxidation and renal inflammation, decreased protein excretion and plasma aldosterone. In the late stages of CRF, NAC alone and in combination with spironolactone, attenuated hypertrophy of the heart and adrenals and reduced hypertension. In mice with CRF, NAC also reduced nitrotyrosine expression and inhibited the progression of atherosclerotic lesions. [41]
6) Diabetic nephropathy
In the kidney of rats with streptozotocininduced diabetes mellitus, either angiotensin receptor blockade or angiotensin converting enzyme inhibition prevented the development of oxidative damage in the kidney, thereby indicating a role of angiotensin II in renal oxidative stress in early diabetic nephropathy. [42] Results from several studies have shown that anti-oxidants marginally improved renal function in diabetic rats [43] as well as in humans. [44],[45] The antioxidant á-lipoic acid, which previously showed promise in the treatment of diabetic neuropathy, attenuated albuminuria, glomerosclerosis and tubulointerstitial fibrosis in longterm treatment of 16-week diabetic rats. [46] This correlated with the reduction of renal NADPH oxidase expression and activity and ROS excretion.
In humans, it was reported that higher levels of 8-OH-G, a marker of oxidative damage to DNA, were found in type-1 and type-2 diabetic patients, patients with diabetic complications, patients with diabetic nephropathy and albuminuria. [27]
7) Drug-induced nephropathy
The generation of free oxygen radicals is one of the possible mechanisms by which several drugs exert their nephrotoxic effects. It was suggested that oxidative stress might underlie in the pathogenesis of vancomycin (VCM)induced nephrotoxicity. Nephrotoxicity due to VCM might be caused by indirect generation of ROS associated with inflammatory events in vivo. [47] ROS have been also proposed as the causative agents of cell death in various models of toxic renal failure including cisplatin, [48] aminoglycosides [49] and doxorubicin (DOX)induced nephropathy. [50] The involvement of ROS has also been documented in the etiology of ifosfamide (IFO)-induced Fanconi syndrome. Ifosfamide has been reported to cause renal GSH depletion and lipid peroxide accumulation. [51]
| The Pharmacological Properties of TQ | | |
Several studies have been conducted, particularly during the past two decades, on the effects of N. sativa seed extract or its active compound TQ on various body systems in vivo or in vitro . [5],[52]These pharmacological effects are shown in [Table 2]. Among these effects, the anti-oxidant and the anti-inflammatory properties are here in reviewed.
Anti-oxidant properties
More than 35 studies have addressed the in vivo and in vitro antitoxic properties of TQ. [52] TQ and a synthetic structurally-related tertbutylhydroquinone, efficiently inhibited irondependent microsomal lipid peroxidation in vitro in a concentration-dependent manner. [53] Stimulation of polymorphonuclear leukocytes with TQ showed protective action against the damaging effects of O 2-, generated either photochemically or biochemically, indicating its potent O - scavenger activity. [54]
Prophylactic treatment of mice with TQ, one hour before carbontetrachloride (CCl4) injection, ameliorated hepatotoxicity of CCl4 as evidenced by the significant reduction of the elevated levels of serum liver enzymes, and significant increase of the hepatic GSH content. [55] Also, TQ prevented the ischemia/reperfusioninduced alterations in gastric mucosal GSH and Super Oxide Dismutase (SOD) in rats. [56]
Anti-inflammatory properties
Progression and persistence of acute or chronic state of inflammation is mediated by a number of mediators including eicosanoids, oxidants, cytokines, and lytic enzymes secreted by the inflammatory cells, macrophages and neutrophils. [57] Inflammation is also mediated by two main enzymes, cyclooxygenase (COX) and lipoxygenase (LO). [58] COX generates prostaglandins (PGEs) and thromboxane from arachidonic acid, while LO catalyzes the formation of leukotriens (LTs). Therefore, both PGEs and LTs function as the main mediators of allergy and inflammation. [59] TQ inhibited both COX and LO pathways of arachidonate metabolism in rat peritoneal leukocytes stimulated with calcium ionophore A23187, as shown by dose-dependent inhibition of thromboxane B2 and LTs levels. Thus, inhibition of both COX and LO pathways is a key factor mediating the anti-inflammatory effects of TQ. [60]
The use of TQ has also been shown to have anti-inflammatory effects in several inflammatory diseases, including experimental allergic encephalomyelitis (EAE), [61] colitis, [62] and arthritis. [63]
| The Experimental Use of TQ in Animal Models of Kidney Diseases | | |
Badary and co-workers investigated the effect of TQ on the nephropathy and oxidative stress induced by DOX in rats. It significantly lowered serum urea, triglycerides, and total cholesterol. Similarly, triglycerides, total cholesterol and lipid peroxides in the kidneys of TQtreated rats were decreased significantly compared with DOX alone. It was concluded that TQ suppressed DOX-induced nephrosis. [64]
Oral supplementation of TQ in drinking water rendered rats significantly less susceptible to IFO-induced renal abnormalities. Also, IFOinduced glucosuria, phosphaturia and Glutathione S-Transferase (GST) enzymuria were significantly less pronounced in rats that received TQ. [51] Additionally, TQ supplementation in drinking water resulted in a complete reversal of gentamicin-induced increase in blood urea, creatinine and lipid peroxides. In addition, it decreased GSH, ATP, GSH-Px and catalase enzymes to the control values. Moreover, histopathological examination of kidney tissues confirmed the biochemical data, where-in TQ supplementation prevented gentamicin-induced degenerative changes in kidney tissues. [65]
| Anti-oxidant Agents in Drug-induced Nephropathy | | |
Based on the previously reported evidence of the role of ROS in different forms of kidney diseases, the role of anti-oxidant agents was studied in different conditions. Several animal models have been used to study the possible role of anti-oxidants of natural origin in attenuating drug-induced nephropathy.
Omega-3 fatty acids favorably modified chronic CsA nephrotoxicity in Sprague Dawley rats. [66] Omega-3 at a dose of 100 mg/kg/day was co-administered with CsA (100 mg/kg/ day) for 80 days. CsA is known to induce tubular atrophy, interstitial fibrosis, and chronic inflammatory cell infiltration. Treatment with Omega-3, significantly improved tubular atrophy and interstitial fibrosis but not chronic inflammatory cell infiltration.
Anti-oxidant foods like garlic and black grape, [67],[68] were also studied in CsA nephrotoxicity. [69] CsA increased Malondialdehyde (MDA) levels and decreased Catalase enzyme activity in the kidneys of Sprague Dawley rats. These effects were reversed by oral administration of aqueous garlic and black grape extracts. They also decreased the glomerular sclerosis, vascular congestion, focal tubular necrosis and thyroidation induced by CsA.
Cisplatin is an extensively used synthetic anticancer drug, which is known for its oxidative stress-mediated severe nephrotoxicity. [70] Several anti-oxidants, including TQ, have been experimentally used to minimize its nephrotoxicity. [Table 3] shows the comparison of the clinical effects of TQ with some of the other known anti-oxidant agents such as Vita-mins E and C, Selenium, Curcumin and Lyco-pene, a naturally occurring carotenoid. A single injection of cisplatin was used to induce nephrotoxicity in different animal models. Treatment with anti-oxidants, either pre, post, or both, were used to alleviate cispalatin-induced nephrotoxicity. [Table 3] shows that TQ achieved the best clinical effects manifested in this animal model of drug-induced nephroto-xicity. It induced the highest percentage of reduction in urea and creatinine and increase in creatinine clearance, compared to cisplatin only group as well as with the use of different anti-oxidants.
| Conclusion | | |
TQ is the main active ingredient of N. sativa seeds, one of the most promising medicinal plants with many therapeutic effects. One of its most important effects is its anti-oxidant activity. It acts as an anion scavenger that neutralizes oxygen radicals. Several studies have proved the usefulness of TQ in ameliorating the nephrotoxicity induced by drugs that exert their adverse effects through generation of ROS. Also, none of the studies reported that the use of TQ in moderate doses had appreciable toxic effects. These results should raise the intriguing possibility that TQ may have a beneficial adjunctive effect similar to Flax seed and 3-Omega fatty acids. As such, efficacy of TQ to retard progression in chronic kidney diseases should be tested in patients with acute and chronic renal diseases.[90]
| References | | |
| 1. | Goreja WG. Black Seed: Natural Medical Remedy. Amazing Herbs Press. 2003. New York. Ref Type: Generic  |
| 2. | Al Rowais NA: Herbal medicine in the treatment of diabetes mellitus. Saudi Med J 2002;23:1327-31. |
| 3. | Kalus U, Pruss A, Bystron J, et al. Effect of Nigella sativa (black seed) on subjective feeling in patients with allergic diseases. Phytother Res 2003;17:1209-14. [PUBMED] [FULLTEXT] |
| 4. | Akhtar MS, Riffat S. Field trial of Saussurea lappa roots against nematodes and Nigella sativa seeds against cestodes in children. J Pak Med Assoc 1991;41:185-7. [PUBMED] |
| 5. | Ali BH, Blunden G. Pharmacological and toxicological properties of Nigella sativa. Phytother Res 2003;17:299-305. [PUBMED] [FULLTEXT] |
| 6. | Ghosheh OA, Houdi AA, Crooks PA. High performance liquid chromatographic analysis of the pharmacologically active quinones and related compounds in the oil of the black seed (Nigella sativa L.). J Pharm Biomed Anal 1999;19:757-62. |
| 7. | Waris G, Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog 2006;5:14. [PUBMED]  |
| 8. | Orient A, Donko A, Szabo A, Leto TL, Geiszt M. Novel sources of reactive oxygen species in the human body. Nephrol Dial Transplant 2007;22:1281-8. |
| 9. | Gorin Y, Ricono JM, Wagner B, et al. Angiotensin II-induced ERK1/ERK2 activation and protein synthesis are redoxdependent in glomerular mesangial cells. Biochem J 2004; 381:231-9. [PUBMED] [FULLTEXT] |
| 10. | Araujo M, Welch WJ. Oxidative stress and nitric oxide in kidney function. Curr Opin Nephrol Hypertens 2006;15:72-7. [PUBMED] [FULLTEXT] |
| 11. | Klahr S. Urinary tract obstruction. Semin Nephrol 2001;21:133-45. [PUBMED] |
| 12. | Scheuer H, Gwinner W, Hohbach J, et al. Oxidant stress in hyperlipidemia-induced renal damage. Am J Physiol Renal Physiol 2000; 278:F63-74. [PUBMED] [FULLTEXT] |
| 13. | Wheeler DC, Chana RS, Topley N, Petersen MM, Davies M, Williams JD. Oxidation of low density lipoprotein by mesangial cells may promote glomerular injury. Kidney Int 1994; 45:1628-36. [PUBMED] |
| 14. | Galle J. Atherosclerosis and arteriitis: implications for therapy of cardiovascular disease. Herz 2004;29:4-11. [PUBMED] [FULLTEXT] |
| 15. | Sakatsume M, Kadomura M, Sakata I, et al. Novel glomerular lipoprotein deposits associated with apolipoprotein E2 homozygosity. Kidney Int 2001;59:1911-8. [PUBMED] [FULLTEXT] |
| 16. | Ozaki M, Yamada Y, Matoba K, et al. Phospholipase A2 activity in ox-LDL-stimulated mesangial cells and modulation by alphatocopherol. Kidney Int Suppl 1999;71:S171-3. [PUBMED] |
| 17. | Chen HC, Tan MS, Guh JY, Tsai JH, Lai YL. Native and oxidized low-density lipoproteins enhance superoxide production from diabetic rat glomeruli. Kidney Blood Press Res 2000; 23:133-7. [PUBMED] [FULLTEXT] |
| 18. | Shah SV, Kamat SR. Respiratory distress in scorpion bite. J Assoc Physicians India 1989; 37:292-3. [PUBMED] |
| 19. | Zager RA, Burkhart K. Myoglobin toxicity in proximal human kidney cells: roles of Fe, Ca2+, H2O2, and terminal mitochondrial electron transport. Kidney Int 1997;51:728-38. [PUBMED] |
| 20. | Agarwal A, Balla J, Balla G, et al. Renal tubular epithelial cells mimic endothelial cells upon exposure to oxidized LDL. Am J Physiol 1996;271:F814-23. [PUBMED] [FULLTEXT] |
| 21. | Vielhauer V, Anders HJ, Mack M, et al. Obstructive nephropathy in the mouse: progressive fibrosis correlates with tubulointerstitial chemokine expression and accumulation of CC chemokine receptor 2- and 5positive leukocytes. J Am Soc Nephrol 2001; 12:1173-87. [PUBMED] [FULLTEXT] |
| 22. | Ou ZL, Natori Y, Natori Y. Gene expression of CC chemokines in experimental acute tubulointerstitial nephritis. J Lab Clin Med 1999;133: 41-7. [PUBMED] [FULLTEXT] |
| 23. | Nickenig G, Strehlow K, Baumer AT, et al. Negative feedback regulation of reactive oxygen species on AT1 receptor gene expression. Br J Pharmacol 2000;131:795-803. |
| 24. | Berry C, Hamilton CA, Brosnan MJ, et al. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation 2000;101:220612. [PUBMED] [FULLTEXT] |
| 25. | Himmelfarb J, Hakim RM. Oxidative stress in uremia. Curr Opin Nephrol Hypertens 2003; 12:593-8. [PUBMED] [FULLTEXT] |
| 26. | Shah SV, Baricos WH, Basci A. Degradation of human glomerular basement membrane by stimulated neutrophils. Activation of a metalloproteinase(s) by reactive oxygen metabolites. J Clin Invest 1987;79:25-31. |
| 27. | Shah SV, Baliga R, Rajapurkar M, Fonseca VA. Oxidants in chronic kidney disease. J Am Soc Nephrol 2007;18:16-28. [PUBMED] [FULLTEXT] |
| 28. | Rehan A, Johnson KJ, Wiggins RC, Kunkel RG, Ward PA. Evidence for the role of oxygen radicals in acute nephrotoxic nephritis. Lab Invest 1984;51:396-403. [PUBMED] |
| 29. | Boyce NW, Holdsworth SR. Hydroxyl radical mediation of immune renal injury by desferrioxamine. Kidney Int 1986;30:813-7. [PUBMED] |
| 30. | Budisavljevic MN, Hodge L, Barber K, et al. Oxidative stress in the pathogenesis of experimental mesangial proliferative glomerulonephritis. Am J Physiol Renal Physiol 2003; 285:F1138-48. [PUBMED] [FULLTEXT] |
| 31. | Kurata H, Takaoka M, Kubo Y, et al. Protective effect of nitric oxide on ischemia/reperfusioninduced renal injury and endothelin-1 overproduction. Eur J Pharmacol 2005;517:232-9. [PUBMED] [FULLTEXT] |
| 32. | Efrati S, Averbukh M, Berman S, et al. NAcetylcysteine ameliorates lithium-induced renal failure in rats. Nephrol Dial Transplant 2005;20:65-70. [PUBMED] [FULLTEXT] |
| 33. | Fuller TF, Freise CE, Feng S, Niemann CU. Ischemic preconditioning improves rat kidney graft function after severe ischemia/reperfusion injury. Transplant Proc 2005;37:377-8. [PUBMED] [FULLTEXT] |
| 34. | Sun K, Kiss E, Bedke J, et al. Role of xanthine oxidoreductase in experimental acute renalallograft rejection. Transplantation 2004;77: 1683-92. [PUBMED] [FULLTEXT] |
| 35. | Chander V, Chopra K. Molsidomine, a nitric oxide donor and L-arginine protects against rhabdomyolysis-induced myoglobinuric acute renal failure. Biochim Biophys Acta 2005; 1723:208-14. [PUBMED] [FULLTEXT] |
| 36. | Tahara M, Nakayama M, Jin MB, et al. A radical scavenger, edaravone, protects canine kidneys from ischemia-reperfusion injury after 72 hours of cold preservation and autotransplantation. Transplantation 2005;80:213-21. [PUBMED] [FULLTEXT] |
| 37. | Erbas H, Aydogdu N, Kaymak K. Effects of N-acetylcysteine on arginase, ornithine and nitric oxide in renal ischemia-reperfusion injury. Pharmacol Res 2004;50:523-7. [PUBMED] [FULLTEXT] |
| 38. | Himmelfarb J, McMonagle E, Freedman S, et al. Oxidative stress is increased in critically ill patients with acute renal failure. J Am Soc Nephrol 2004;15:2449-56. [PUBMED] [FULLTEXT] |
| 39. | Sindhu RK, Ehdaie A, Farmand F, et al. Expression of catalase and glutathione peroxidase in renal insufficiency. Biochim Biophys Acta 2005;1743:86-92. [PUBMED] [FULLTEXT] |
| 40. | Shimizu MH, Coimbra TM, de Araujo M, Menezes LF, Seguro AC. N-acetylcysteine attenuates the progression of chronic renal failure. Kidney Int 2005;68:2208-17. [PUBMED] [FULLTEXT] |
| 41. | Ivanovski O, Szumilak D, Nguyen-Khoa T, et al. The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int 2005;67: 2288-94. [PUBMED] [FULLTEXT] |
| 42. | Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 2002;61:186-94. [PUBMED] [FULLTEXT] |
| 43. | Chander PN, Gealekman O, Brodsky SV, et al. Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. J Am Soc Nephrol 2004;15:2391-403. [PUBMED] [FULLTEXT] |
| 44. | Chiarelli F, Santilli F, Sabatino G, et al. Effects of vitamin E supplementation on intracellular antioxidant enzyme production in adolescents with type 1 diabetes and early microangiopathy. Pediatr Res 2004;56:720-5. [PUBMED] [FULLTEXT] |
| 45. | Yasuda G, Kuji T, Hasegawa K, et al. Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease. Ren Fail 2004;26:411-8. [PUBMED] |
| 46. | Bhatti F, Mankhey RW, Asico L, Quinn MT, Welch WJ, Maric C. Mechanisms of antioxidant and pro-oxidant effects of alphalipoic acid in the diabetic and nondiabetic kidney. Kidney Int 2005;67:1371-80. [PUBMED] [FULLTEXT] |
| 47. | Nishino Y, Takemura S, Minamiyama Y, et al. Targeting superoxide dismutase to renal proximal tubule cells attenuates vancomycininduced nephrotoxicity in rats. Free Radic Res 2003;37:373-9. [PUBMED] |
| 48. | Cuzzocrea S, Mazzon E, Dugo L, et al. A role for superoxide in gentamicin-mediated nephropathy in rats. Eur J Pharmacol 2002;450:67-76. [PUBMED] [FULLTEXT] |
| 49. | Parlakpinar H, Tasdemir S, Polat A, et al. Protective role of caffeic acid phenethyl ester (cape) on gentamicin-induced acute renal toxicity in rats. Toxicology 2005;207:169-77. [PUBMED] [FULLTEXT] |
| 50. | Bertani T, Cutillo F, Zoja C, Broggini M, Remuzzi G. Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney Int 1986;30:488-96. |
| 51. | Badary OA. Thymoquinone attenuates ifosfamideinduced Fanconi syndrome in rats and ehances its antitumor activity in mice. J Ethnopharmacol 1999;67:135-42. |
| 52. | Salem ML. Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int Immunopharmacol 2005;5:1749-70. |
| 53. | Badary OA, Taha RA, Gamal el-Din AM, Abdel-Wahab MH. Thymoquinone is a potent superoxide anion scavenger. Drug Chem Toxicol 2003;26:87-98. [PUBMED] [FULLTEXT] |
| 54. | Nagi MN, Mansour MA. Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: a possible mechanism of protection. Pharmacol Res 2000;41:283-9. [PUBMED] [FULLTEXT] |
| 55. | Enomoto S, Asano R, Iwahori Y, et al. Hematological studies on black cumin oil from the seeds of Nigella sativa L. Biol Pharm Bull 2001;24:307-10. [PUBMED] [FULLTEXT] |
| 56. | El Abhar HS, Abdallah DM, Saleh S. Gastroprotective activity of Nigella sativa oil and its constituent, thymoquinone, against gastric mucosal injury induced by ischaemia/reperfusion in rats. J Ethnopharmacol 2003;84:251-8. |
| 57. | Lefkowitz DL, Gelderman MP, Fuhrmann SR, et al. Neutrophilic myeloperoxidase-macrophage interactions perpetuate chronic inflammation associated with experimental arthritis. Clin Immunol 1999;91:145-55. [PUBMED] [FULLTEXT] |
| 58. | Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-16. [PUBMED] [FULLTEXT] |
| 59. | van Ryn J, Trummlitz G, Pairet M. COX-2 selectivity and inflammatory processes. Curr Med Chem 2000;7:1145-61. [PUBMED] [FULLTEXT] |
| 60. | Mansour M, Tornhamre S. Inhibition of 5lipoxygenase and leukotriene C4 synthase in human blood cells by thymoquinone. J Enzyme Inhib Med Chem 2004;19:431-6. [PUBMED] [FULLTEXT] |
| 61. | Mohamed A, Shoker A, Bendjelloul F, et al. Improvement of experimental allergic encephalomyelitis (EAE) by thymoquinone; an oxidative stress inhibitor. Biomed Sci Instrum 2003;39:440-5. [PUBMED] |
| 62. | Mahgoub AA. Thymoquinone protects against experimental colitis in rats. Toxicol Lett 2003; 143:133-43. [PUBMED] [FULLTEXT] |
| 63. | Tekeoglu I, Dogan A, Ediz L, Budancamanak M, Demirel A. Effects of thymoquinone (volatile oil of black cumin) on rheumatoid arthritis in rat models. Phytother Res 2007; 21:895-7. [PUBMED] [FULLTEXT] |
| 64. | Badary OA, Abdel-Naim AB, Abdel-Wahab MH, Hamada FM. The influence of thymoquinone on doxorubicin-induced hyperlipidemic nephropathy in rats. Toxicology 2000;143:21926. [PUBMED] [FULLTEXT] |
| 65. | Sayed-Ahmed MM, Nagi MN. Thymoquinone supplementation prevents the development of gentamicin-induced acute renal toxicity in rats. Clin Exp Pharmacol Physiol 2007;34:399-405. [PUBMED] [FULLTEXT] |
| 66. | Sabry A, El Husseini A, Sheashaa H, et al. Colchicine vs. omega-3 fatty acids for prevention of chronic cyclosporine nephrotoxicity in Sprague Dawley rats: an experimental animal model. Arch Med Res 2006;37:933-40. |
| 67. | Alcolea JF, Cano A, Acosta M, Arnao MB. Hydrophilic and lipophilic antioxidant activities of grapes. Nahrung 2002;46:353-6. [PUBMED] |
| 68. | Banerjee SK, Mukherjee PK, Maulik SK. Garlic as an antioxidant: the good, the bad and the ugly. Phytother Res 2003;17:97-106. [PUBMED] [FULLTEXT] |
| 69. | Durak I, Cetin R, Candir O, Devrim E, Kilicoglu B, Avci A. Black grape and garlic extracts protect against cyclosporine A nephrotoxicity. Immunol Invest 2007;36:105-14. |
| 70. | Ajith TA, Usha S, Nivitha V. Ascorbic acid and alpha-tocopherol protect anticancer drug cisplatin induced nephrotoxicity in mice: a comparative study. Clin Chim Acta 2007;375: 82-6. [PUBMED] [FULLTEXT] |
| 71. | Koo DD, Welsh KI, McLaren AJ, Roake JA, Morris PJ, Fuggle SV. Cadaver versus living donor kidneys: impact of donor factors on antigen induction before transplantation. Kidney Int 1999;56:1551-9. [PUBMED] [FULLTEXT] |
| 72. | Sung RS, Althoen M, Howell TA, Ojo AO, Merion RM. Excess risk of renal allograft loss associated with cigarette smoking. Transplantation 2001;71:1752-7. |
| 73. | Waller JR, Nicholson ML. Molecular mechanisms of renal allograft fibrosis. Br J Surg 2001;88:1429-41. [PUBMED] [FULLTEXT] |
| 74. | Kansas GS. Selectins and their ligands: current concepts and controversies. Blood 1996;88: 3259-87. [PUBMED] [FULLTEXT] |
| 75. | Takemoto SK, Terasaki PI, Gjertson DW, Cecka JM. Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med 2000;343:1078-84. [PUBMED] [FULLTEXT] |
| 76. | Sarwal M, Chua MS, Kambham N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003;349:125-38. [PUBMED] [FULLTEXT] |
| 77. | Gebauer BS, Hricik DE, Atallah A, et al. Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool. Am J Transplant 2002;2:85766. [PUBMED] [FULLTEXT] |
| 78. | Mauiyyedi S, Colvin RB. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens 2002;11:609-18. [PUBMED] [FULLTEXT] |
| 79. | Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002;359:741-6. |
| 80. | Weinberg A, Zhang L, Hayward AR. Alloreactive cytotoxic CD4+ responses elicited by cytomegalovirus-infected endothelial cells: role of MHC class I antigens. Viral Immunol 2000;13:37-47. [PUBMED] |
| 81. | Kosch M, Hausberg M, Suwelack B. Studies on effects of calcineurin inhibitor withdrawal on arterial distensibility and endothelial function in renal transplant recipients. Transplantation 2003;76:1516-9. [PUBMED] [FULLTEXT] |
| 82. | Cohen SM. Current immuno-suppression in liver transplantation. Am J Ther 2002;9:11925. [PUBMED] [FULLTEXT] |
| 83. | Al Majed AA, Daba MH, Asiri YA, et al. Thymoquinone-induced relaxation of guinea- pig isolated trachea. Res Commun Mol Pathol Pharmacol 2001;110:333-45. |
| 84. | Abdel-Fattah AM, Matsumoto K, Watanabe H. Antinociceptive effects of Nigella sativa oil and its major component, thymoquinone, in mice. Eur J Pharmacol 2000;400:89-97. [PUBMED] [FULLTEXT] |
| 85. | el Tahir KE, Ashour MM, al Harbi MM. The cardiovascular actions of the volatile oil of the black seed (Nigella sativa) in rats: elucidation of the mechanism of action. Gen Pharmacol 1993;24:1123-31. |
| 86. | Calvino J, Lens XM, Romero R, SanchezGuisande D. Long-term anti-proteinuric effect of Losartan in renal transplant recipients treated for hypertension. Nephrol Dial Transplant 2000;15:82-6. |
| 87. | Aboul-Ela EI. Cytogenetic studies on Nigella sativa seeds extract and thymoquinone on mouse cells infected with schistosomiasis using karyotyping. Mutat Res 2002;516:11-7. [PUBMED] [FULLTEXT] |
| 88. | Badary OA, Nagi MN, al Shabanah OA, al Sawaf HA, al Sohaibani MO, al Bekairi AM. Thymoquinone ameliorates the nephrotoxicity induced by cisplatin in rodents and potentiates its antitumor activity. Can J Physiol Pharmacol 1997;75:1356-61. |
| 89. | Antunes LM, Darin JD, Bianchi NL. Effects of the antioxidants curcumin or selenium on cisplatin-induced nephrotoxicity and lipid peroxidation in rats. Pharmacol Res 2001; 43:145-50. |
| 90. | Atessahin A, Yilmaz S, Karahan I, Ceribasi AO, Karaoglu A. Effects of lycopene against cisplatin-induced nephrotoxicity and oxidative stress in rats. Toxicology 2005;212:116-23. [PUBMED] [FULLTEXT] |
Correspondence Address:
Ahmed Shoker
Department of Medicine Division of Nephrology University of Saskatchewan 103 Hospital Drive, Saskatoon SK S7N 0W8
Canada
  | Check |
PMID: 19736468 
[Figure 1], [Figure 2]
[Table 1], [Table 2], [Table 3] |
|
| This article has been cited by | | 1 |
Nanothymoquinone, a novel hepatotargeted delivery system for treating CCl4 mediated hepatotoxicity in rats |
|
| Verma, S.K. and Rastogi, S. and Javed, K. and Akhtar, M. and Arora, I. and Samim, M. | | Journal of Materials Chemistry B. 2013; 1(23): 2956-2966 | | [Pubmed] | | | 2 |
Formulation and evaluation of a new biodegradable periodontal chip containing thymoquinone in a chitosan base for the management of chronic periodontitis |
|
| Al-Bayaty, F.H. and Kamaruddin, A.A. and Ismail, M.A. and Abdulla, M.A. | | Journal of Nanomaterials. 2013; 2013(397308) | | [Pubmed] | | | 3 |
A review on the role of quinones in renal disorders |
|
| Madeo, J. and Zubair, A. and Marianne, F. | | SpringerPlus. 2013; 2(1): 1-8 | | [Pubmed] | | | 4 |
Maternal supplementation of diabetic mice with thymoquinone protects their offspring from abnormal obesity and diabetes by modulating their lipid profile and free radical production and restoring lymphocyte proliferation via PI3K/AKT signaling |
|
| Badr, G. and Mahmoud, M.H. and Farhat, K. and Waly, H. and Al-Abdin, O.Z. and Rabah, D.M. | | Lipids in Health and Disease. 2013; 12(1) | | [Pubmed] | | | 5 |
A case study report of acute renal failure associated with Nigella sativa in a diabetic patient |
|
| Arslan, E. and Sayin, S. and Demirbaş, Ş. and Çakar, M. and Somak, N.G. and Yeşilkaya, Ş. and Saǧlam, K. | | Journal of Chinese Integrative Medicine. 2013; 11(1): 64-66 | | [Pubmed] | | | 6 |
Chemomodulatory effect of nigella sativa and green tea against fe-nta-mediated renal oxidative damage in rat |
|
| El Boghdady, N.A. and Darwish, H.A. | | Journal of Food Biochemistry. 2012; 36(6): 756-765 | | [Pubmed] | | | 7 |
The effect of thymoquinone treatment on the levels of serum autoimmune anti-islet cell antibodies in type 1 diabetic rats |
|
| Osman, M.T. and Adnan, A. and Omar, E. and Jamal, A. | | Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2012; 3(4): 677-686 | | [Pubmed] | | | 8 |
Immunomodulatory effect of Nigella sativa oil treatment in iron deficiency anemia caused by refractory coeliac disease |
|
| Osman, M.T. and Taha, B.I. and Al-Duboni, G. and Muhamed, L.A. | | Research Journal of Pharmaceutical, Biological and Chemical Sciences. 2012; 3(4): 887-895 | | [Pubmed] | | | 9 |
Thymoquinone prevents and ameliorates dextran sulfate sodium-induced colitis in mice |
|
| Lei, X. and Liu, M. and Yang, Z. and Ji, M. and Guo, X. and Dong, W. | | Digestive Diseases and Sciences. 2012; 57(9): 2296-2303 | | [Pubmed] | | | 10 |
Thymoquinone improves aging-related endothelial dysfunction in the rat mesenteric artery |
|
| Idris-Khodja, N. and Schini-Kerth, V. | | Naunyn-Schmiedebergæs Archives of Pharmacology. 2012; 385(7): 749-758 | | [Pubmed] | | | 11 |
Cadmium-induced hepatotoxicity and its abrogation by thymoquinone |
|
| Zafeer, M.F. and Waseem, M. and Chaudhary, S. and Parvez, S. | | Journal of Biochemical and Molecular Toxicology. 2012; 26(5): 199-205 | | [Pubmed] | | | 12 |
Regulation of renal organic anion and cation transporters by thymoquinone in cisplatin induced kidney injury |
|
| Ulu, R. and Dogukan, A. and Tuzcu, M. and Gencoglu, H. and Ulas, M. and Ilhan, N. and Muqbil, I. and Mohammad, R.M. and Kucuk, O. and Sahin, K. | | Food and Chemical Toxicology. 2012; 50(5): 1675-1679 | | [Pubmed] | | | 13 |
Preventive effects of thymoquinone in a rat periodontitis model: A morphometric and histopathological study |
|
| Ozdemir, H. and Kara, M.I. and Erciyas, K. and Ozer, H. and Ay, S. | | Journal of Periodontal Research. 2012; 47(1): 74-80 | | [Pubmed] | | | 14 |
Thymoquinone ameliorates the immunological and histological changes induced by exposure to imidacloprid insecticide |
|
| Mohany, M. and El-Feki, M. and Refaat, I. and Garraud, O. and Badr, G. | | Journal of Toxicological Sciences. 2012; 37(1): 1-11 | | [Pubmed] | | | 15 |
Cyclic voltammetry, spectroelectrochemistry and electron spin resonance as combined tools to study thymoquinone in aprotic medium |
|
| Petrucci, R. and Marrosu, G. and Astolfi, P. and Lupidi, G. and Greci, L. | | Electrochimica Acta. 2012; 60: 230-238 | | [Pubmed] | | | 16 |
Effects of vitamin E and thymoquinone on physiological and histological characteristics of heat-stressed male mice |
|
| Al-Zahrani, S. and Kandeal, S. and Mohany, M. and Badr, G. | | African Journal of Pharmacy and Pharmacology. 2011; 5(19): 2174-2183 | | [Pubmed] | | | 17 |
Thymoquinone rich fraction from Nigella sativa and thymoquinone are cytotoxic towards colon and leukemic carcinoma cell lines |
|
| Norsharina, I. and Maznah, I. and Aied, A.-A. and Ghanya, A.-N. | | Journal of Medicinal Plants Research. 2011; 5(15): 3359-3366 | | [Pubmed] | | | 18 |
Ameliorative effect of thymoquinone on ovalbumin-induced allergic conjunctivitis in Balb/c mice |
|
| Hayat, K. and Asim, M.R. and Nawaz, M. and Li, M. and Zhang, L. and Sun, N. | | Current Eye Research. 2011; 36(7): 591-598 | | [Pubmed] | | | 19 |
Amelioration of nitrobenzene-induced nephrotoxicity by the ethanol extract of the herb Euphorbia hirta |
|
| Suganya, S. and Sophia, D. and Raj, C.A. and Rathi, M.A. and Thirumoorthi, L. and Meenakshi, P. and Kumar, D.G. and Gopalakrishnan, V.K. | | Pharmacognosy Research. 2011; 3(3): 201-207 | | [Pubmed] | | | 20 |
Identification of novel anti-inflammatory agents from ayurvedic medicine for prevention of chronic diseases: "Reverse pharmacology" and "Bedside to bench" approach |
|
| Aggarwal, B.B. and Prasad, S. and Reuter, S. and Kannappan, R. and Yadav, V.R. and Park, B. and Kim, J.H. and Gupta, S.C. and Phromnoi, K. and Sundaram, C. and Prasad, S. and Chaturvedi, M.M. and Sung, B. | | Current Drug Targets. 2011; 12(11): 1595-1653 | | [Pubmed] | | | 21 |
Effect of thymoquinone on hepatorenal dysfunction and alteration of CYP3A1 and spermidine/spermine N-1-acetyl-transferase gene expression induced by renal ischaemia-reperfusion in rats |
|
| Awad, A.S. and Kamel, R. and Sherief, M.-A.E. | | Journal of Pharmacy and Pharmacology. 2011; 63(8): 1037-1042 | | [Pubmed] | | | 22 |
Attenuated combined action of cyclosporine A and hyperlipidemia on atherogenesis in rabbits by thymoquinone |
|
| Shoker, A. and Ragheb, A. and Attia, A. and Elbarbry, F. and Prasad, K. | | Evidence-based Complementary and Alternative Medicine. 2011; 2011(620319) | | [Pubmed] | | | 23 |
Nigella sativa seed extract and its bioactive compound thymoquinone: The new melanogens causing hyperpigmentation in the wall lizard melanophores |
|
| Ali, S.A. and Meitei, K.V. | | Journal of Pharmacy and Pharmacology. 2011; 63(5): 741-746 | | [Pubmed] | | | 24 |
Potential health benefits of sulforaphane: A RE of the experimental, clinical and epidemiological evidences and underlying mechanisms |
|
| Elbarbry, F. and Elrody, N. | | Journal of Medicinal Plants Research. 2011; 5(4): 473-484 | | [Pubmed] | | | 25 |
Elucidation of molecular mechanisms underlying the protective effects of thymoquinone against rheumatoid arthritis |
|
| Vaillancourt, F. and Silva, P. and Shi, Q. and Fahmi, H. and Fernandes, J.C. and Benderdour, M. | | Journal of Cellular Biochemistry. 2011; 112(1): 107-117 | | [Pubmed] | | | 26 |
Egg yield and quality in laying hens fed diets containing black cumin seed and/or white wormwood leaves |
|
| Yagoub, B.A. and Amin, A.E. and El Bagir, N.M. and Alhaidary, A. and Mohamed, H.E. and Beyn, A.C. | | Journal of Animal and Veterinary Advances. 2010; 9(20): 2600-2603 | | [Pubmed] | | | 27 |
Clinical laboratory serum values in rabbits fed diets containing black cumin seed |
|
| El Bagir, N.M. and Farah, I.T.O. and Alhaidary, A. and Mohamed, H.E. and Beynen, A.C. | | Journal of Animal and Veterinary Advances. 2010; 9(19): 2532-2536 | | [Pubmed] | | | 28 |
Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: Role of reactive oxygen species |
|
| Koka, P.S. and Mondal, D. and Schultz, M. and Abdel-Mageed, A.B. and Agrawal, K.C. | | Experimental Biology and Medicine. 2010; 235(6): 751-760 | | [Pubmed] | | | 29 |
Clear cell carcinoma of the ovary: Potential pathogenic mechanisms (review) |
|
| Kajihara, H. and Yamada, Y. and Kanayama, S. and Furukawa, N. and Noguchi, T. and Haruta, S. and Yoshida, S. and Sado, T. and Oi, H. and Kobayashi, H. | | Oncology Reports. 2010; 23(5): 1193-1203 | | [Pubmed] | |
|
|
|
|
|
|
|
|
|
|
|
|
| Article Access Statistics | | | Viewed | 13694 | | | Printed | 204 | | | Emailed | 0 | | | PDF Downloaded | 4402 | | | Comments | [Add] | | | Cited by others | 29 | | |
|
|
